Mechanisms and Targeted Therapy of Airway Basal Cell Dysfunction in Bronchiolitis Obliterans Syndrome
NCT07018804 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5
Last updated 2025-06-12
Summary
This experimental study aims to investigate the pathogenesis of bronchiolitis obliterans syndrome (BOS) and provide a basis for clinical diagnosis and treatment. The core research question is: whether there is a causal relationship between stem cell dysfunction induced by the inflammatory microenvironment and airway injury repair during the pathological process of BOS? Researchers will collect alveolar lavage fluid specimens from participants and healthy individuals to isolate distal small airway stem cells for subsequent scientific research and comparative analysis, thereby revealing the pathological mechanisms of BOS, exploring precise intervention targets, and developing innovative therapeutic strategies to improve patient prognosis, long-term survival rates, and quality of life.
Conditions
- Bronchiolitis Obliterans Syndrome (BOS)
Interventions
- PROCEDURE
-
Bronchoscopic brushing
The collected samples are digested with tissue collagenase for the culture of airway basal cells (BCs).
- GENETIC
-
Single - cell cloning
After primary BCs are expanded in the P1 passage, single-cell cloning libraries are established by planting them into 384-well cell culture plates in a single-cell per well format using a flow chamber cell sorter. Ten samples are selected from the expandable clones for the identification of differentiation and proliferation capabilities, while the remaining clones are cryopreserved.
- GENETIC
-
Cell function identification
For single-cell samples of each patient, in vitro expansion culture is performed to observe the morphology of cells at each passage and calculate the clonogenic rate. Immunofluorescence technique is used to detect the expression of the cell proliferation marker Ki67, and the proliferation capacity is evaluated by combining with the CCK8 assay. Cells at passages P3-P5 are seeded on the permeable membrane of cell culture inserts at a density of \\(10\^6\\) cells/cm², and after 21 days of culture, the differentiated structures are collected. The expression of ciliated cell marker Ace-Tubulin and goblet cell marker MUC5AC is detected to assess the differentiation capacity. Meanwhile, cells are injected subcutaneously into NSG mice at \\(10\^6\\) cells/injection site for in vivo differentiation for 28 days, and the differentiated structures are collected for pathological analysis.
- GENETIC
-
Identification of local microenvironmental changes
The air-liquid interface (ALI) differentiation culture medium is collected, and cell debris is removed by high-speed centrifugation. The supernatant is then collected to extract proteins. Target proteins are purified via immunoprecipitation or affinity chromatography, followed by desalting and concentration for mass spectrometry analysis to detect inflammatory cytokines and extracellular matrix (ECM). Real-time PCR and Western blot techniques are used to measure the expression levels of epithelial markers, mesenchymal markers, and ECM in cells across all groups, thereby evaluating changes in the local microenvironment around small airways.
- GENETIC
-
Gene editing
After plasmid construction, based on gene function, the CRISPR-Cas9-sgRNA (all-in-one) plasmid is transiently transfected into expanded single-cell strains via Nucleofection to knockout the target gene, or the CRISPR-dCas9 fusion-sgRNA plasmid is transiently transfected to activate or inhibit the target gene. After 3-5 days of culture, viable cells are sorted by FACS, and single cells are seeded into 96-well plates for two additional passages of expansion. Samples are collected for Sanger sequencing to screen successfully constructed cell lines.
- PROCEDURE
-
Prevention of ferret airway basal cell transplantation
Before surgery, basal cells (BCs) of recipient ferrets are collected by bronchoscopic brushing, followed by in vitro culture and identification. Prior to the onset of BOS, the cells are injected into recipient ferrets via bronchoscopy. Outcomes including ferret survival rate, body weight, CT imaging, and lung tissue pathology are collected to evaluate the preventive effect of BCs on BOS.
- PROCEDURE
-
Transplantation treatment of ferret airway basal cells
Stable cell lines with target gene knockdown are established in ferret basal cells (BCs). After ferrets develop bronchiolitis obliterans syndrome (BOS), the constructed cell lines are transplanted into recipient ferrets to validate the therapeutic effect of gene-corrected BCs on the disease.
Sponsors & Collaborators
-
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
lead OTHER
Principal Investigators
-
Xiaoyang Yang, DM · Department of Hematology, Haikou People's Hospital
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-01-01
- Primary Completion
- 2027-06-30
- Completion
- 2028-06-30
Countries
- China
Study Locations
More Related Trials
-
Treatment of COPD by Autologous Transplantation of Bronchial Basal Cells
NCT03156673 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Autologous Bronchial Basal Cells Transplantation for Treatment of Chronic Obstructive Pulmonary Disease (COPD)
NCT03092648 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
COPD Treatment by Transplantation of Autologous Bronchial Basal Cells
NCT05594303 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Autologous Bronchial Basal Cell Transplantation for Treatment of COPD
NCT03188627 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
REGEND001 Autologous Basal Layer Stem Cell Transplantation for Bronchiectasis: A Translational Application Study
NCT06987214 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Prognosis of Bronchiectasis in Children--A Multicenter Prospective Cohort Study
NCT02564731 ·Status: UNKNOWN
-
Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis
NCT02745184 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Role of Fibrocytes in the Bronchial Remodelling of Chronic Obstructive Pulmonary Disease
NCT01692444 ·Status: COMPLETED
-
Follow-up Study of Autologous Transplantation of P63+ Lung Progenitor Cells for Treatment of Bronchiectasis
NCT06164093 ·Status: COMPLETED ·Phase: NA
-
Definition of the Status of the Human Lung Stem Cell Niches ex Vivo in Tissue Biopsies Performed in Patients With Emphysema and Interstitial Fibrosis
NCT02705144 ·Status: UNKNOWN
-
Assessment of an Exhaled Breath Test to Detect Bronchiectasis
NCT05293314 ·Status: COMPLETED
-
Exhaled Breath Condensate Assessment in Stable Non-Cystic Fibrotic Bronchiectasis
NCT03643263 ·Status: COMPLETED
-
Autologous Lung Stem Cell Transplantation in Patients With Interstitial Lung Diseases
NCT02796781 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Bronchial Epithelium of Children With Post-infectious Bronchiolitis Obliterans
NCT06140901 ·Status: RECRUITING ·Phase: NA
-
Regeneration of Bronchial Epithelium During Chronic Obstructive Pulmonary Disease
NCT02873988 ·Status: COMPLETED
-
Smoking-induced EGF-dependent Reprogramming of Airway Basal Cell Function
NCT01974180 ·Status: TERMINATED
-
Lung Function, LCI, Bronchial Inflammation and Epigenetics of Patients With BO
NCT02627833 ·Status: UNKNOWN
-
Impulse Oscillation to Evaluate Diagnostic Efficacy in Patients With Chronic Airway Disease
NCT04668027 ·Status: UNKNOWN ·Phase: NA
-
Air Pollution and Health of COPD Patients
NCT05076630 ·Status: COMPLETED
-
Multicenter Cohort Study on Predicting Bronchiectasis Progression, Complications, and Prognosis Using Multi-omics
NCT07263373 ·Status: COMPLETED
-
Bronchial Inflammation in Patients With Bronchiolithis Obliterans
NCT01633385 ·Status: COMPLETED
-
Identification of Microbiome and Metabolome of Bronchiectasis in Chinese Population.
NCT04490447 ·Status: UNKNOWN
-
The Establishment of China Bronchiectasis Registry and Research Collaboration
NCT03643653 ·Status: RECRUITING
-
Treatment in Patients Hospitalized With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
NCT02219360 ·Status: UNKNOWN
-
Value of Bronchoalveolar Lavage with Acetylcysteine in the Treatment of Bronchiectasis.
NCT06726356 ·Status: RECRUITING ·Phase: NA